サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427809

フィブラート系薬の世界市場レポート 2024

Fibrate Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
フィブラート系薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

フィブラート系薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.0%の年間複合成長率（CAGR）で44億5,000万米ドルに成長すると予想されます。予測期間の予想される拡大は、治療ガイドラインの進化、残留リスクの重視、精密医療の進歩、ドラッグデリバリーの革新によるものと考えられます。予測期間中に予想される主な動向には、代替製剤の開発、遠隔医療の統合、高リスクグループにおけるフィブラート系薬の利用、トリグリセリド値の目標、HDL上昇への焦点などが含まれます。

心疾患の発生率の予想される増加は、将来のフィブラート系薬市場の成長を促進する態勢が整っています。心臓病には、冠状動脈性心疾患、先天性心疾患など、心臓と血管に影響を与えるさまざまな状態が含まれます。フィブラート系薬は、すでに循環器系疾患に罹患している人の更なる心臓発作や脳卒中を予防する治療法として機能し、それによってフィブラート系薬市場の拡大に貢献します。疾病管理予防センターのハイライトによると、2023年 5月の時点で、2021年の375,476人の死亡原因は冠状動脈性心疾患であると推定されています。さらに、2022年 12月にニューヨーク州政府が発表したデータでは、心臓病が人々の命を奪っていることが明らかになりました。米国では年間約697,000人が死亡しており、死亡者の5人に1人を占めています。この中には、毎年約80万5,000人のアメリカ人が心臓発作を経験しており、そのうち60万5,000人が初めての心臓発作、20万人が以前の心臓発作によるものです。したがって、心疾患の発生率の増加は、フィブラート系薬市場の成長の重要な推進力となっています。

心血管疾患を対象とした政府の取り組みは、将来のフィブラート系薬市場の成長に大きく貢献すると予想されます。これらの取り組みには通常、心血管疾患、その危険因子、予防策についての意識を高めることを目的とした公衆衛生キャンペーンが含まれます。その結果、フィブラート系薬が一般的に処方される高脂血症（血液中の脂質レベルの上昇）などの症状の診断を受ける人が増える可能性があります。一例として、2023年 10月にオーストラリア政府は心血管保健ミッションに2億2,000万米ドルを割り当てました。この取り組みは、研究者、医療専門家、業界利害関係者、患者を結集させ、オーストラリア全国民の心臓と血管の健康、脳卒中の予防と治療に革新的な改善をもたらすものです。したがって、心血管疾患に焦点を当てた政府の取り組みの拡大により、フィブラート系薬市場を推進する準備が整っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のフィブラート系薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • クロフィブラート
  • フェノフィブラーテス
  • フェノフィブリン酸
  • ゲムフィブロジル
  • その他の薬物
  • 世界のフィブラート系薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 高コレステロール血症
  • 心臓発作
  • その他の適応症
  • 世界のフィブラート系薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界のフィブラート系薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のフィブラート系薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のフィブラート系薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • フィブラート系薬市場の競合情勢
  • フィブラート系薬市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck &Co Inc.
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Kowa Company Ltd.
  • Bristol-Myers Squibb Co
  • Abbott Laboratories
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Company
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Daiichi Sankyo Co Ltd.
  • Fresenius Kabi AG
  • Macleods Pharmaceuticals Ltd .
  • Sun Pharmaceutical Industries Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13653

Fibrate drugs are prescribed medications designed to lower triglyceride levels and elevate high-density lipoprotein (HDL) cholesterol levels. They are commonly employed for the treatment of hypercholesterolemia or mixed dyslipidemia.

The primary categories of fibrate drugs encompass clofibrate, fenofibrates, fenofibric acids, gemfibrozil, and others. Clofibrate, identified as a fibric acid derivative, is employed for the management of hypertriglyceridemia and elevated cholesterol levels. Its primary function is to regulate and control increased levels of cholesterol and triglycerides. Fibrate drugs are utilized in the treatment of conditions such as hypercholesterolemia and heart attacks, and they are available at hospital pharmacies, online pharmacies, and retail pharmacies. End-users of fibrate drugs include hospitals, homecare, specialty clinics, and others.

The fibrate drugs treatment market research report is one of a series of new reports from The Business Research Company that provides fibrate drugs treatment market statistics, including the fibrate drugs treatment industry's global market size, regional shares, competitors with an fibrate drugs treatment market share, detailed fibrate drugs treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fibrate drugs treatment industry. This fibrate drugs treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibrate drugs market size has grown steadily in recent years. It will grow from $3.36 billion in 2023 to $3.53 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The increase observed in the historical period can be ascribed to the emergence of lipid management, a focus on cholesterol management, clinical research and trials, efforts in cardiovascular risk reduction, and the utilization of combination therapies.

The fibrate drugs market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated expansion in the forecast period can be credited to the evolution of treatment guidelines, emphasis on residual risk, advancements in precision medicine, and innovation in drug delivery. Key trends expected in the forecast period involve the development of alternative formulations, integration of telemedicine, utilization of fibrates in high-risk groups, targeting triglyceride levels, and a focus on raising HDL.

The anticipated rise in the incidence of cardiac diseases is poised to fuel the growth of the fibrate drug market in the future. Cardiac diseases encompass a spectrum of conditions affecting the heart and blood vessels, including coronary heart disease, congenital heart disease, and others. Fibrates serve as a treatment to prevent further heart attacks and strokes in individuals already affected by circulatory system conditions, thereby contributing to the expansion of the fibrate drug market. As of May 2023, according to the Centers for Disease Control and Prevention Highlights, coronary heart disease was estimated to be responsible for 375,476 deaths in 2021. Additionally, data published by the New York government in December 2022 revealed that heart disease claims the lives of approximately 697,000 people annually in the United States, accounting for 1 in every 5 fatalities. This includes around 805,000 Americans experiencing a heart attack each year, with 605,000 being first-time occurrences and 200,000 resulting from previous heart attacks. Consequently, the increased incidence of cardiac diseases is a significant driver for the growth of the fibrate drug market.

Government initiatives targeting cardiovascular diseases are expected to make a substantial contribution to the growth of the fibrate drugs market in the future. These initiatives typically involve public health campaigns aimed at increasing awareness about cardiovascular diseases, their risk factors, and preventive measures. Consequently, more individuals may receive diagnoses for conditions such as hyperlipidemia (elevated lipid levels in the blood), for which fibrates are commonly prescribed. As an illustration, in October 2023, the government of Australia allocated $220 million to the Cardiovascular Health Mission. This initiative brings together researchers, health professionals, industry stakeholders, and patients to make transformative improvements in heart and vascular health, as well as stroke prevention and treatment for all Australians. Hence, the growing government initiatives focused on cardiovascular diseases are poised to propel the fibrate drugs market.

Product innovations stand out as a prominent trend gaining traction in the fibrate drugs market, with major companies in the sector actively pursuing the development of inventive solutions to maintain their market standing. An illustrative example is Lupin Limited, an innovation-led transnational pharmaceutical company based in India, which, in November 2021, introduced an authorized generic version of Antara (Fenofibrate) Capsules in 30 mg and 90 mg. These fenofibrate capsules are recommended as adjunctive therapy for adult patients with primary hypercholesterolemia, aiming to lower elevated levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides (TG), and apolipoprotein B (Apo B), while raising levels of high-density lipoprotein cholesterol (HDL-C).

Major players in the fibrate drugs market are directing their efforts toward the integration of digital health solutions tailored for cardiovascular diseases. The trend involves healthcare providers increasingly prescribing combinations of fibrates with other lipid-lowering agents, such as statins, to achieve synergistic effects and address multiple aspects of dyslipidemia. An instance of this is seen in August 2023 when GE Healthcare, a US-based manufacturing company, launched CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relevant to disease progression from various sources. This tool aims to drive evidence-based clinical decision support guided by current AFib guidelines.

In February 2023, AstraZeneca PLC, a UK-based pharmaceuticals company, acquired CinCor Pharma Inc for an undisclosed amount. This strategic acquisition is intended to strengthen AstraZeneca's cardiorenal pipeline by adding baxdrostat, a novel aldosterone synthase inhibitor under development for lowering blood pressure. Baxdrostat, a candidate medication from CinCor, aligns with AstraZeneca's mission to advance the treatment of cardiorenal illnesses. Elevated aldosterone levels are associated with hypertension and various cardiorenal conditions, including coronary artery disease and chronic kidney disease. CinCor Pharma Inc., based in the US, specializes in the development of fibrate drugs.

Major companies operating in the fibrate drugs market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Bristol-Myers Squibb Co, Abbott Laboratories, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co Ltd., Fresenius Kabi AG, Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd., Natco Pharma, Hetero Drugs Ltd

North America was the largest region in the fibrate drugs market in 2023. The regions covered in the fibrate drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fibrate drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibrate drugs market consists of sales of medicines for high cholesterol, hyperlipoproteinemia, and hypertriglyceridemia. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibrate Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibrate drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibrate drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibrate drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Clofibrate; Fenofibrates; Fenofibric Acids; Gemfibrozil; Other Drugs
  • 2) By Indication: Hypercholesterolemia; Heart Attacks; Other Indications
  • 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co Inc.; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fibrate Drugs Market Characteristics

3. Fibrate Drugs Market Trends And Strategies

4. Fibrate Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Fibrate Drugs Market Size and Growth

  • 5.1. Global Fibrate Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Fibrate Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Fibrate Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Fibrate Drugs Market Segmentation

  • 6.1. Global Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clofibrate
  • Fenofibrates
  • Fenofibric Acids
  • Gemfibrozil
  • Other Drugs
  • 6.2. Global Fibrate Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hypercholesterolemia
  • Heart Attacks
  • Other Indications
  • 6.3. Global Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.4. Global Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Fibrate Drugs Market Regional And Country Analysis

  • 7.1. Global Fibrate Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Fibrate Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Fibrate Drugs Market

  • 8.1. Asia-Pacific Fibrate Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Fibrate Drugs Market

  • 9.1. China Fibrate Drugs Market Overview
  • 9.2. China Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Fibrate Drugs Market

  • 10.1. India Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Fibrate Drugs Market

  • 11.1. Japan Fibrate Drugs Market Overview
  • 11.2. Japan Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Fibrate Drugs Market

  • 12.1. Australia Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Fibrate Drugs Market

  • 13.1. Indonesia Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Fibrate Drugs Market

  • 14.1. South Korea Fibrate Drugs Market Overview
  • 14.2. South Korea Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Fibrate Drugs Market

  • 15.1. Western Europe Fibrate Drugs Market Overview
  • 15.2. Western Europe Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Fibrate Drugs Market

  • 16.1. UK Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Fibrate Drugs Market

  • 17.1. Germany Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Fibrate Drugs Market

  • 18.1. France Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Fibrate Drugs Market

  • 19.1. Italy Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Fibrate Drugs Market

  • 20.1. Spain Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Fibrate Drugs Market

  • 21.1. Eastern Europe Fibrate Drugs Market Overview
  • 21.2. Eastern Europe Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Fibrate Drugs Market

  • 22.1. Russia Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Fibrate Drugs Market

  • 23.1. North America Fibrate Drugs Market Overview
  • 23.2. North America Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Fibrate Drugs Market

  • 24.1. USA Fibrate Drugs Market Overview
  • 24.2. USA Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Fibrate Drugs Market

  • 25.1. Canada Fibrate Drugs Market Overview
  • 25.2. Canada Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Fibrate Drugs Market

  • 26.1. South America Fibrate Drugs Market Overview
  • 26.2. South America Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Fibrate Drugs Market

  • 27.1. Brazil Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Fibrate Drugs Market

  • 28.1. Middle East Fibrate Drugs Market Overview
  • 28.2. Middle East Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Fibrate Drugs Market

  • 29.1. Africa Fibrate Drugs Market Overview
  • 29.2. Africa Fibrate Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Fibrate Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Fibrate Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Fibrate Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Fibrate Drugs Market Competitive Landscape
  • 30.2. Fibrate Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Fibrate Drugs Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi SA
  • 31.3. Kowa Company Ltd.
  • 31.4. Bristol-Myers Squibb Co
  • 31.5. Abbott Laboratories
  • 31.6. AstraZeneca plc
  • 31.7. GlaxoSmithKline Plc
  • 31.8. Takeda Pharmaceutical Company
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Mylan N.V.
  • 31.12. Daiichi Sankyo Co Ltd.
  • 31.13. Fresenius Kabi AG
  • 31.14. Macleods Pharmaceuticals Ltd .
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Fibrate Drugs Market Competitive Benchmarking

33. Global Fibrate Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Fibrate Drugs Market

35. Fibrate Drugs Market Future Outlook and Potential Analysis

  • 35.1 Fibrate Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Fibrate Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Fibrate Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer